Immunolabelling of the inhibin/activin-ßC subunit in normal and malignant human uterine cervical tissue and cervical cancer cell lines

Oncology Reports

Volumn 25, Issue 1, 2011, Pages 147-152

  Blankenstein, Thomas ^a   Jückstock, Julia ^a   Shabani, Naim ^a,b   Kunze, Susanne ^a   Brüning, Ansgar ^a   Bergauer, Florian ^a   Mylonas, Ioannis ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b Klinikum Neuperlach   (Germany)

Author keywords

Cervical cancer; Cervical cancer cell lines; Immunofluorescence; Immunohistochemistry; Inhibin C

Indexed keywords

ACTIVIN; ACTIVIN C; INHIBIN; INHIBIN C; PROTEIN SUBUNIT; UNCLASSIFIED DRUG;

ANTIBODY LABELING; ARTICLE; BASEMENT MEMBRANE; CANCER CELL CULTURE; CARCINOGENESIS; CASKI CELL; CELL MEMBRANE; CELL TYPE; CONTROLLED STUDY; FEMALE; HELA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCOMPETENT CELL; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN SYNTHESIS; SQUAMOUS CELL CARCINOMA; STAINING; TUMOR CELL LINE; UTERINE CERVIX; UTERINE CERVIX CANCER; UTERUS CARCINOMA;

CELL LINE, TUMOR; CERVIX UTERI; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOHISTOCHEMISTRY; INHIBIN-BETA SUBUNITS; INHIBINS; UTERINE CERVICAL NEOPLASMS;

EID: 78650725173     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or-00001054     Document Type: Article

References (49)

1. Franco EL, Schlecht NF and Saslow D: The epidemiology of cervical cancer. Cancer J 9: 348-359, 2003.
2. Waggoner SE: Cervical cancer. Lancet 361: 2217-2225, 2003.
3. Munoz N, Bosch FX, De Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ and Meijer CJ: Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348: 518-527, 2003. (Pubitemid 36159887)
4. Massad LS, Einstein M, Myers E, Wheeler CM, Wentzensen N and Solomon D: The impact of human papillomavirus vaccination on cervical cancer prevention efforts. Gynecol Oncol 114: 360-364, 2009.
5. Zur Hausen H: Papillomaviruses in the causation of human cancers -a brief historical account. Virology 348: 260-265, 2009.
6. Vale W, Wiater E, Gray P, Harrison C, Bilezikjian L and Choe S: Activins and inhibins and their signaling. Ann NY Acad Sci 1038: 142-147, 2004.
7. Xia Y and Schneyer AL: The biology of activin: recent advances in structure, regulation and function. J Endocrinol 202: 1-12, 2009.
8. Hötten G, Neidhardt H, Schneider C and Pohl J: Cloning of a new member of the TGF-beta family: a putative new activin beta C chain. Biochem Biophys Res Commun 206: 608-613,1995.
9. Hashimoto O, Tsuchida K, Ushiro Y, Hosoi Y, Hoshi N, Sugino H and Hasegawa Y: cDNA cloning and expression of human activin betaE subunit. Mol Cell Endocrinol 194: 117-122, 2002.
10. Fang J, Yin W, Smiley E, Wang SQ and Bonadio J: Molecular cloning of the mouse activin beta E subunit gene. Biochem Biophys Res Commun 228: 669-674, 1996.
11. Bergauer F, Bruning A, Shabani N, Blankenstein T, Juckstock J, Dian D and Mylonas I: Inhibin/activin-betaE subunit in normal and malignant human cervical tissue and cervical cancer cell lines. J Mol Histol 40: 353-359, 2009.
12. Kimmich T, Bruning A, Kaufl SD, Makovitzky J, Kuhn C, Jeschke U, Friese K and Mylonas I: Inhibin/activin-betaC and -betaE subunits in the Ishikawa human endometrial adenocarcinoma cell line. Arch Gynecol Obstet 282: 185-191, 2010.
13. Käufl SD, Makovitzky J, Kuhn C, Kunze S, Jeschke U and Mylonas I: Inhibin/activin-betaC subunit in human endometrial adenocarcinomas and HEC-1a adenocarcinoma cell line. In Vivo 282: 185-191, 2010.
14. Gingelmaier A, Bruning A, Kimmich T, Makovitzky J, Bergauer F, Schiessl B, Friese K and Mylonas I: Inhibin/activinbetaE subunit is expressed in normal and pathological human placental tissue including chorionic carcinoma cell lines. Arch Gynecol Obstet: January 6, 2010 (Epub ahead of print)
15. Weissenbacher T, Bruning A, Kimmich T, Makovitzky J, Gingelmaier A and Mylonas I: Immunohistochemical labeling of the inhibin/activin betaC subunit in normal human placental tissue and chorionic carcinoma cell lines. J Histochem Cytochem 58: 751-757, 2010.
16. Mellor SL, Cranfield M, Ries R, Pedersen J, Cancilla B, De Kretser D, Groome NP, Mason AJ and Risbridger GP: Localization of activin beta(A)-, beta(B)-, and beta(C)-subunits in humanprostate and evidence for formation of new activin heterodimers of beta(C)-subunit. J Clin Endocrinol Metab 85:4851-4858, 2000.
17. Ushiro Y, Hashimoto O, Seki M, Hachiya A, Shoji H and Hasegawa Y: Analysis of the function of activin beta(C) subunit using recombinant protein. J Reprod Dev 52: 487-495, 2006.
18. Risbridger GP, Schmitt JF and Robertson DM: Activins and inhibins in endocrine and other tumors. Endocr Rev 22: 836-858, 2001.
19. Mylonas I, Shabani N, Vogl J, Makovitzky J, Kunze S, Kuhn C, Schulze S, Friese K and Jeschke U: Inhibin/activin subunits are immunohistochemically expressed in complete and partial hydatidiform moles. Anticancer Res 27: 1995-2000, 2007.
20. Mylonas I, Makovitzky J, Hoeing A, Richter DU, Vogl J, Schulze S, Jeschke U, Briese V and Friese K: Inhibin/activin subunits beta-A (-betaA) and beta-B (-betaB) are differentially localised in normal, hyperplastic and malignant human endometrial tissue. Acta Histochem 108: 1-11, 2006.
21. Mylonas I, Schiessl B, Jeschke U, Vogl J, Makrigiannakis A, Kuhn C, Kunze S, Schulze S, Kainer F and Friese K: Expression of inhibin/activin subunits alpha (-alpha), beta A (-beta (A)) and beta B (-beta (B)) in placental tissue of normal and intrauterine growth restricted (IUGR) pregnancies. J Mol Histol 37: 43-52, 2006. (Pubitemid 44421092)
22. Jückstock J, Brüning A, Blankenstein T, Kunze S, Shaban N, Bergauer F and Mylonas I: Immunolabelling of the inhibinbetaA and -betaB subunit in normal and malignant human cervical tissue and cervical cancer cell line. Int J Gynecol Cancer 20: 1117-1124, 2010.
23. Worbs S, Shabani N, Mayr D, Gingelmaier A, Makrigiannakis A, Kuhn C, Jeschke U, Kupka MS, Friese K and Mylonas I: Expression of the inhibin/activin subunits (-alpha, -betaA and -betaB) in normal and carcinogenic endometrial tissue: Possible immunohistochemical differentiation markers. Oncol Rep 17: 97-104, 2007.
24. Mylonas I: Inhibin-alpha, -betaA and -betaB subunits in uterine non-endometrioid carcinomas: prognostic significance and clinical implications. Eur J Cancer 46: 2485-2493, 2010.
25. Petraglia F, Florio P, Luisi S, Gallo R, Gadducci A, Vigano P, Di Blasio AM, Genazzani AR and Vale W: Expression and secretion of inhibin and activin in normal and neoplastic uterine tissues. High levels of serum activin A in women with endometrial and cervical carcinoma. J Clin Endocrinol Metab 83: 1194-1200, 1998.
26. Mylonas I, Jeschke U, Wiest I, Hoeing A, Vogl J, Shabani N, Kuhn C, Schulze S, Kupka MS and Friese K: Inhibin/activin subunits alpha, beta-A and beta-B are differentially expressed in normal human endometrium throughout the menstrual cycle. Histochem Cell Biol 122: 461-471, 2004.
27. Mylonas I, Worbs S, Shabani N, Kuhn C, Kunze S, Schulze S, Dian D, Gingelmaier A, Schindlbeck C, Bruning A, Sommer H, Jeschke U and Friese K: Inhibin-alpha subunit is an independent prognostic parameter in human endometrial carcinomas: analysis of inhibin/activin-alpha, -betaA and -betaB subunits in 302 cases. Eur J Cancer 45: 1304-1314, 2009.
28. Mylonas I, Makovitzky J, Richter DU, Jeschke U, Briese V and Friese K: Expression of the inhibin-alpha subunit in normal, hyperplastic and malignant endometrial tissue: an immunohistochemical analysis. Gynecol Oncol 93: 92-97, 2004.
29. Otani T, Minami S, Kokawa K, Shikone T, Yamoto M and Nakano R: Immunohistochemical localization of activin A in human endometrial tissues during the menstrual cycle and in early pregnancy. Obstet Gynecol 91: 685-692, 1998.
30. Käufl SD, Kuhn C, Kunze S, Shabani N, Brüning A, Friese K and Mylonas I: Inhibin/activin-betaC subunit does not represent a prognostic parameter in human endometrial cancer. Arch Gynecol Obstet: August 4, 2010 (Epub ahead of print)
31. Bruning A, Makovitzky J, Gingelmaier A, Friese K and Mylonas I: The metastasis-associated genes MTA1 and MTA3 are abundantly expressed in human placenta and chorionic carcinoma cells. Histochem Cell Biol 132: 33-38, 2009.
32. Mylonas I, Schiessl B, Jeschke U, Vogl J, Makrigiannakis A, Kuhn C, Schulze S, Kainer F and Friese K: Expression of inhibin/activin subunits alpha (-alpha), betaA (-betaA), and betaB (-betaB) in placental tissue of normal, preeclamptic and HELLP pregnancies. Endocr Pathol 17: 19-34, 2006.
33. Mylonas I: Prognostic significance and clinical importance of estrogen receptor alpha and beta in human endometrioid adenocarcinomas. Oncol Rep 24: 385-393, 2010.
34. Gold EJ, O'Bryan MK, Mellor SL, Cranfield M, Risbridger GP, Groome NP and Fleming JS: Cell-specific expression of beta C-activin in the rat reproductive tract, adrenal and liver. Mol Cell Endocrinol 222: 61-69, 2004.
35. Chabicovsky M, Herkner K and Rossmanith W: Overexpression of activin beta(C) or activin beta(E) in the mouse liver inhibits regenerative deoxyribonucleic acid synthesis of hepatic cells. Endocrinology 144: 3497-3504, 2003.
36. Mylonas I, Jeschke U, Shabani N, Kuhn C, Friese K and Gerber B: Inhibin/activin subunits (inhibin-alpha, -betaA and -betaB) are differentially expressed in human breast cancer and their metastasis. Oncol Rep 13: 81-88, 2005.
37. Beattie GM, Lopez AD, Bucay N, Hinton A, Firpo MT, King CC and Hayek A: Activin A maintains pluripotency of human embryonic stem cells in the absence of feeder layers. Stem Cells 23: 489-495, 2005.
38. De Kretser DM, Hedger MP, Loveland KL and Phillips DJ: Inhibins, activins and follistatin in reproduction. Hum Reprod Update 8: 529-541, 2002.
39. Robson NC, Wei H, McAlpine T, Kirkpatrick N, Cebon J and Maraskovsky E: Activin-A attenuates several human natural killer cell functions. Blood 113: 3218-3225, 2009.
40. Phillips DJ, De Kretser DM and Hedger MP: Activin and related proteins in inflammation: not just interested bystanders. Cytokine Growth Factor Rev 20: 153-164, 2009.
41. Chen YG, Lui HM, Lin SL, Lee JM and Ying SY: Regulation of cell proliferation, apoptosis, and carcinogenesis by activin. Exp Biol Med (Maywood) 227: 75-87, 2002.
42. Vejda S, Cranfield M, Peter B, Mellor SL, Groome N, Schulte-Hermann R and Rossmanith W: Expression and dimerization of the rat activin subunits betaC and betaE: evidence for the ormation of novel activin dimers. J Mol Endocrinol 28: 137-148, 2002.
43. Zhang YQ, Shibata H, Schrewe H and Kojima I: Reciprocal expression of mRNA for inhibin betaC and betaA subunits in hepatocytes. Endocr J 44: 759-764, 1997.
44. Gold EJ, Zhang X, Wheatley AM, Mellor SL, Cranfield M, Risbridger GP, Groome NP and Fleming JS: betaA-and betaCactivin, follistatin, activin receptor mRNA and betaC-activin peptide expression during rat liver regeneration. J Mol Endocrinol 34: 505-515, 2005.
45. Mellor SL, Ball EM, O'Connor AE, Ethier JF, Cranfield M, Schmitt JF, Phillips DJ, Groome NP and Risbridger GP: Activin betaC-subunit heterodimers provide a new mechanism of regulating activin levels in the prostate. Endocrinology 114: 4410-4419, 2003.
46. Vejda S, Erlach N, Peter B, Drucker C, Rossmanith W, Pohl J, Schulte-Hermann R and Grusch M: Expression of activins C and E induces apoptosis in human and rat hepatoma cells. Carcinogenesis 24: 1801-1809, 2003.
47. Wada W, Medina JJ, Kuwano H and Kojima I: Comparison of the function of the beta(C) and beta(E) subunits of activin in AML12 hepatocytes. Endocr J 52: 169-175, 2005.
48. Butler CM, Gold EJ and Risbridger GP: Should activin betaC be more than a fading snapshot in the activin/TGFbeta family album? Cytokine Growth Factor Rev 16: 377-385, 2005
49. Gold E, Jetly N, O'Bryan MK, Meachem S, Srinivasan D, Behuria S, Sanchez-Partida LG, Woodruff T, Hedwards S, Wang H, McDougall H, Casey V, Niranjan B, Patella S and Risbridger G: Activin C antagonizes activin A in vitro and overexpression leads to pathologies in vivo. Am J Pathol 174: 184-195,2009.